Donanemab in early symptomatic Alzheimer’s disease

Abstract

### Key learning points The authors of a phase 3 trial involving people with early Alzheimer’s disease (AD) reported that although donanemab produced a small reduction in clinical progression compared with placebo, it was associated with some serious adverse effects.1 The TRAILBLAZER-ALZ 2 trial was a 76-week, phase 3, randomised, double-blind, placebo-controlled study that recruited participants aged 60–85 years with early symptomatic AD, a Mini-Mental State Examination score of 20–28 and confirmed amyloid and tau pathology assessed by positron emission tomography (PET) scans.1 A total of 1736 …